|
[Related PubMed/MEDLINE]
Total Number of Papers: 243
|
|
|
| |
|
[Display Entries]
|
|
>> all entries
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2020 |
A Novel Microglia-Specific Transcriptional Signature Correlates With Behavioral Deficits in Neuropsychiatric Lupus. |
DAM |
| 2 |
2020 |
Absence of Neuronal Autoantibodies in Neuropsychiatric Systemic Lupus Erythematosus. |
CSF, NMDARs, SLE |
| 3 |
2020 |
Advances in the diagnosis, pathogenesis and treatment of neuropsychiatric systemic lupus erythematosus. |
SLE |
| 4 |
2020 |
Analysis of brain metabolites by gas chromatography-mass spectrometry reveals the risk-benefit concerns of prednisone in MRL/lpr lupus mice. |
GC-MS, PCA, SLE |
| 5 |
2020 |
Association of anti-NR2 and U1RNP antibodies with neurotoxic inflammatory mediators in cerebrospinal fluid from patients with neuropsychiatric systemic lupus erythematosus. |
auto Abs, BBB, CSF, DN, DP, IMs, MIG, NR2 |
| 6 |
2020 |
Clinical Efficacy of Routinely Administered Belimumab on Proteinuria and Neuropsychiatric Lupus. |
BEL, LN, SLE |
| 7 |
2020 |
Comprehensive expression profile of long non-coding RNAs in Peripheral blood mononuclear cells from patients with neuropsychiatric systemic lupus erythematosus. |
DE, GO, lncRNAs, mRNAs, PBMCs |
| 8 |
2020 |
Immunological biomarkers in neuropsychiatric systemic lupus erythematosus: a comparative cross-sectional study from a tertiary care center in South India. |
aCL, beta2GP1, CI, LA, OR, SLE |
| 9 |
2020 |
Is serum TWEAK a useful biomarker of neuropsychiatric systemic lupus erythematosus? |
SLE, SLEDAI, TWEAK |
| 10 |
2020 |
Neuroprotective effect of microglia against impairments of auditory steady-state response induced by anti-P IgG from SLE patients in naive mice. |
ASSR, BBB, EEG |
| 11 |
2020 |
Neuropsychiatric Lupus Erythematosus: Future Directions and Challenges; a Systematic Review and Survey. |
ACR, AUC, CI, PPV |
| 12 |
2020 |
Prevalence of neuropsychiatric lupus in psychosis patients with a positive antinuclear antibody. |
ANA |
| 13 |
2020 |
Prevalence, involved domains, and predictor of cognitive dysfunction in systemic lupus erythematosus. |
CD, ELISA, MoCA, SLE |
| 14 |
2020 |
Prevalence, outcome and prognostic factors of neuropsychiatric systemic lupus erythematosus: A real world single center study. |
CRP, CSF |
| 15 |
2020 |
Quantitative Identification of Functional Connectivity Disturbances in Neuropsychiatric Lupus Based on Resting-State fMRI: A Robust Machine Learning Approach. |
--- |
| 16 |
2020 |
The immunologic etiology of psychiatric manifestations in systemic lupus erythematosus: A narrative review on the role of the blood brain barrier, antibodies, cytokines and chemokines. |
BBB, CSF |
| 17 |
2020 |
What are the latest clinical findings regarding the association of neurotoxic brain antibodies found in the cerebrospinal fluid in patients with autoimmune disorders? |
BBB |
| 18 |
2019 |
A challenging case of neuropsychiatric systematic lupus erythematosus with recurrent antiphospholipid- related stroke: A case report and literature review. |
aPL |
| 19 |
2019 |
Anti-GAPDH Autoantibody Is Associated with Increased Disease Activity and Intracranial Pressure in Systemic Lupus Erythematosus. |
aCL, CRP, ELISA, ESR, Hb, PLT, SLE, SLICC/ACR, WBC |
| 20 |
2019 |
Blood-brain barrier disruption and neuroinflammation as pathophysiological mechanisms of the diffuse manifestations of neuropsychiatric systemic lupus erythematosus. |
BBB, SLE |
| 21 |
2019 |
Cerebral blood flow abnormalities in neuropsychiatric systemic lupus erythematosus. |
aCL, anti-dsDNA |
| 22 |
2019 |
Clinical features of central nervous system infections and experience in differential diagnosis from neuropsychiatric lupus erythematosus in a cohort of 8491 patients with systemic lupus erythematosus. |
AUC, CNS, CSF, SLE |
| 23 |
2019 |
Clinical significance of anti-DNA/N-methyl-D-aspartate receptor 2 antibodies in de novo and post-steroid cases with neuropsychiatric systemic lupus erythematosus. |
HC, NR2 |
| 24 |
2019 |
Clinical, neuroimaging and immunological phenotype of South African neuropsychiatric systemic lupus erythematosus patients. |
MRI, WMH |
| 25 |
2019 |
Downregulation of hippocampal NR2A/2B subunits related to cognitive impairment in a pristane-induced lupus BALB/c mice. |
i.p |
| 26 |
2019 |
Epidemiology, characterization, and diagnosis of neuropsychiatric events in systemic lupus erythematosus. |
--- |
| 27 |
2019 |
Interferon-alpha exacerbates neuropsychiatric phenotypes in lupus-prone mice. |
ELISA, PAS, RT-qPCR |
| 28 |
2019 |
Neuroinflammation in systemic lupus erythematosus - a review. |
BBB, CNS, NPS, SLE |
| 29 |
2019 |
The clinical significance of ubiquitin carboxyl hydrolase L1 and its autoantibody in neuropsychiatric systemic lupus erythematosus. |
CSF, CTD, mNPSLE, NSD, sNPSLE, UCH-L1 |
| 30 |
2019 |
Update on the pathogenesis of central nervous system lupus. |
BBB, CNS |
| 31 |
2019 |
Utility of osteopontin in cerebrospinal fluid as a diagnostic marker for neuropsychiatric systemic lupus erythematosus. |
CSF, LN |
| 32 |
2019 |
[Neuropathology of Neuropsychiatric Systemic Lupus Erythematosus (NPSLE)]. |
--- |
| 33 |
2018 |
A Brain Ring-Enhancing Lesion. |
--- |
| 34 |
2018 |
A Conscious Resting State fMRI Study in SLE Patients Without Major Neuropsychiatric Manifestations. |
HC, ReHo, rs-fMRI, SLE |
| 35 |
2018 |
Blood-brain barrier dysfunction in immuno-mediated neurological diseases. |
AQP4, BBB, MS, NMO, SP |
| 36 |
2018 |
Differences between central nervous system infection and neuropsychiatric systemic lupus erythematosus in patients with systemic lupus erythematosus. |
CNS, CRP, CSF, SLE, SLEDAI |
| 37 |
2018 |
Identification of Levels of Serum Amyloid A and Apolipoprotein A1 in Serum Proteomic Analysis of Neuropsychiatric Systemic Lupus Erythematosus Patients. |
ApoA1, HDL, MS, SAA |
| 38 |
2018 |
Jaw Dystonia and Reversible Basal Ganglia Changes as an Initial Presentation of Systemic Lupus Erythematosus. |
--- |
| 39 |
2018 |
Novel anti-suprabasin antibodies may contribute to the pathogenesis of neuropsychiatric systemic lupus erythematosus. |
CSF, MS, NPH, SBSN, SLE |
| 40 |
2018 |
Prevalence, risk factors, and impact on mortality of neuropsychiatric lupus: a prospective, single-center study. |
ACR, SLEDAI, SLICC |
| 41 |
2018 |
Proteomic approach to profiling immune complex antigens in cerebrospinal fluid samples from patients with central nervous system autoimmune diseases. |
CSF, ICs |
| 42 |
2018 |
Psycho-rheumatic Integration in Systemic Lupus Erythematosus: An Insight into Antibodies Causing Neuropsychiatric Changes. |
NMDAR |
| 43 |
2018 |
Role of serum autoantibodies in blood brain barrier damages in neuropsychiatric systemic lupus erythematosus. |
ACS, BBB |
| 44 |
2018 |
Understanding the Antibody Repertoire in Neuropsychiatric Systemic Lupus Erythematosus and Neuromyelitis Optica Spectrum Disorder: Do They Share Common Targets? |
AQP4, dsDNA, MOG, NMOSD |
| 45 |
2017 |
A case of neuropsychiatric lupus Erythematosus characterized by the Owl's eye sign: a case report. |
SLE |
| 46 |
2017 |
Advanced MRI techniques: biomarkers in neuropsychiatric lupus. |
DTI, GM, SLE, WM |
| 47 |
2017 |
Anti-N-methyl-D-aspartate receptor antibodies are associated with fibromyalgia in patients with systemic lupus erythematosus: a case-control study. |
FM, NMDARs, SLE |
| 48 |
2017 |
Association of anti-triosephosphate isomerase antibodies with aseptic meningitis in patients with neuropsychiatric systemic lupus erythematosus. |
ELISA, TPI |
| 49 |
2017 |
Autoantibodies against myelin sheath and S100beta are associated with cognitive dysfunction in patients with rheumatoid arthritis. |
CNS, DVR, RA, S100beta |
| 50 |
2017 |
Brain MRI in patients with acute confusional state of diffuse psychiatric/neuropsychological syndromes in systemic lupus erythematosus. |
ACS |
| 51 |
2017 |
Central Nervous System Manifestations of Systemic Lupus Erythematosus. |
--- |
| 52 |
2017 |
Differential activation mechanisms of serum C5a in lupus nephritis and neuropsychiatric systemic lupus erythematosus. |
BBB, CSF, LN |
| 53 |
2017 |
Elevated levels of soluble fractalkine and increased expression of CX3CR1 in neuropsychiatric systemic lupus erythematosus. |
CSF, DNPSLE, FNPSLE, sFKN, SLEDAI |
| 54 |
2017 |
Evaluation of blood-brain barrier function by quotient alpha2 macroglobulin and its relationship with interleukin-6 and complement component 3 levels in neuropsychiatric systemic lupus erythematosus. |
ACS, BBB, ELISA, IL, Q C3, Qalpha2MG |
| 55 |
2017 |
Extracellular miR-145, miR-223 and miR-326 expression signature allow for differential diagnosis of immune-mediated neuroinflammatory diseases. |
miRNAs, MS, NMOSD, qRT-PCR, SMAD3, Sp1, SPMS |
| 56 |
2017 |
Neurological Manifestations in Systemic Lupus Erythematosus: A Single Centre Study from North East India. |
ARA, SLE, SLEDAI |
| 57 |
2017 |
Neuropsychiatric Systemic Lupus Erythematosus Involvement: Towards a Tailored Approach to Our Patients? |
--- |
| 58 |
2017 |
Primary Psychiatric Disorder Masking the Diagnosis of Neuropsychiatric Lupus in a Patient with Altered Mental Status: A Case Report. |
AMS, ANA, CSF, MRI, SLE, SLICC |
| 59 |
2017 |
[The clinical significance of anti- ubiquitin C-terminal hydrolase L1 autoantibodies in the diagnosis of neuropsychiatric systemic lupus erythematosus]. |
ELISA, UCHL-1 |
| 60 |
2016 |
A Comprehensive Rehabilitation Approach in a Patient With Serious Neuropsychiatric Systemic Lupus Erythematosus. |
SLE |
| 61 |
2016 |
A meta-analysis of serum and cerebrospinal fluid autoantibodies in neuropsychiatric systemic lupus erythematosus. |
Abs, aCL, aPL, CSF, LA, OR |
| 62 |
2016 |
Antibodies to microtubule-associated protein-2 in the cerebrospinal fluid are a useful diagnostic biomarker for neuropsychiatric systemic lupus erythematosus. |
CSF, MAP-2 |
| 63 |
2016 |
Association of antibodies to the NR1 subunit of N-methyl-D-aspartate receptors with neuropsychiatric systemic lupus erythematosus. |
aa, ELISA, mNR1, NMDA, NR1 |
| 64 |
2016 |
Changes in White Matter Microstructure Suggest an Inflammatory Origin of Neuropsychiatric Systemic Lupus Erythematosus. |
CNS, GM, MTR-HPHs, WM |
| 65 |
2016 |
Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. |
CYC |
| 66 |
2016 |
Evaluation of magnetic resonance imaging abnormalities in juvenile onset neuropsychiatric systemic lupus erythematosus. |
--- |
| 67 |
2016 |
Glial and axonal changes in systemic lupus erythematosus measured with diffusion of intracellular metabolites. |
--- |
| 68 |
2016 |
IL-6, IL-8, IP-10, MCP-1 and G-CSF are significantly increased in cerebrospinal fluid but not in sera of patients with central neuropsychiatric lupus erythematosus. |
CNS, CSF |
| 69 |
2016 |
Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. |
SLICC |
| 70 |
2016 |
Is it relevant to screen young women hospitalized in psychiatric department for neuropsychiatric systemic lupus erythematosus (NPSLE)?: A prospective study of 100 psychiatric inpatients. |
ANA, DNA, ENA, SLE, SSA |
| 71 |
2016 |
Management of Neuropsychiatric Systemic Lupus Erythematosus: Current Approaches and Future Perspectives. |
NP, SLE |
| 72 |
2016 |
Neuropsychiatric manifestations in patients with systemic lupus erythematosus: A study from Iran. |
CVD, SLE |
| 73 |
2016 |
Predictors of clinical outcomes in patients with neuropsychiatric systemic lupus erythematosus. |
CI, CSF, IFN-gamma, IL, OR, TNF-alpha, WV |
| 74 |
2016 |
Quantitative susceptibility mapping in patients with systemic lupus erythematosus: detection of abnormalities in normal-appearing basal ganglia. |
QSM |
| 75 |
2016 |
Relationship Between Clinical and Immunological Features with Magnetic Resonance Imaging Abnormalities in Female Patients with Neuropsychiatric Systemic Lupus Erythematosus. |
CA, CI, MRI, OR, RD, SLEDAI |
| 76 |
2016 |
Soluble alpha-klotho is a potential biomarker associated with neuropsychiatric systemic lupus erythematosus. |
CSF, MS, NMO, SLE, VM |
| 77 |
2016 |
The Neurochemical and Microstructural Changes in the Brain of Systemic Lupus Erythematosus Patients: A Multimodal MRI Study. |
DKI, HCs, PCG, VBM |
| 78 |
2016 |
Utility of TWEAK to assess neuropsychiatric disease activity in systemic lupus erhytematosus. |
CSF, NP, TNF |
| 79 |
2015 |
A multimodal MRI approach to identify and characterize microstructural brain changes in neuropsychiatric systemic lupus erythematosus. |
AD, DTI, FA, FLAIR, HC, MD, MTI, MTR, NAWM, NP, RD, SLE |
| 80 |
2015 |
Anti-NR2A/B Antibodies and Other Major Molecular Mechanisms in the Pathogenesis of Cognitive Dysfunction in Systemic Lupus Erythematosus. |
CNS, SLE |
| 81 |
2015 |
Anti-ribosomal P protein autoantibodies from patients with neuropsychiatric lupus impair memory in mice. |
anti-P, LPS, NSPA |
| 82 |
2015 |
Autoantibody profiling on human proteome microarray for biomarker discovery in cerebrospinal fluid and sera of neuropsychiatric lupus. |
CSF |
| 83 |
2015 |
Automatic Segmentation of the Corpus Callosum Using a Cell-Competition Algorithm: Diffusion Tensor Imaging-Based Evaluation of Callosal Atrophy and Tissue Alterations in Patients With Systemic Lupus Erythematosus. |
CNS, DTI, FA, MD |
| 84 |
2015 |
Behavioral Deficits Are Accompanied by Immunological and Neurochemical Changes in a Mouse Model for Neuropsychiatric Lupus (NP-SLE). |
IDO, IFN-gamma, IL-10, VCAM-1 |
| 85 |
2015 |
Brain MRI in neuropsychiatric lupus: associations with the 1999 ACR case definitions. |
ACR, DWI, MRI |
| 86 |
2015 |
Detection of cerebral microvascular lesions using 7 T MRI in patients with neuropsychiatric systemic lupus erythematosus. |
T1WIs |
| 87 |
2015 |
Discriminating infectious meningitis versus neuropsychiatric involvement in patients with systemic lupus erythematosus: a single-center experience. |
CSF, SLEDAI |
| 88 |
2015 |
Distinguishing the cerebrospinal fluid cytokine profile in neuropsychiatric systemic lupus erythematosus from other autoimmune neurological diseases. |
CSF, FGF, IFN, IL, MS, NMO |
| 89 |
2015 |
Integrative neuroscience approach to neuropsychiatric lupus. |
--- |
| 90 |
2015 |
Intractable headaches, ischemic stroke, and seizures are linked to the presence of anti-beta2GPI antibodies in patients with systemic lupus erythematosus. |
aCL, anti-beta2GPI, aPL, CVD, LA |
| 91 |
2015 |
Neuropsychiatric manifestations associated with anti-endothelial cell antibodies in systemic lupus erythematosus. |
SLE |
| 92 |
2015 |
Non-invasive imaging to monitor lupus nephritis and neuropsychiatric systemic lupus erythematosus. |
CNS, CT, LN, MRI, PET, SLE, US |
| 93 |
2015 |
Pathogenicity of lupus anti-ribosomal P antibodies: role of cross-reacting neuronal surface P antigen in glutamatergic transmission and plasticity in a mouse model. |
AMPAR, EPSP, LTP, NMDAR, NSPA |
| 94 |
2015 |
Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLE. |
RNFL, SD-OCT |
| 95 |
2015 |
Serum neuron specific enolase - a novel indicator for neuropsychiatric systemic lupus erythematosus? |
ACR, NP, NSE, SLAM, SLE |
| 96 |
2015 |
Successful Treatment of Lupus Cerebrovascular Disease with Mycophenolate Mofetil. |
AZ, IL-6, MMF |
| 97 |
2015 |
TRPC6 gene variants and neuropsychiatric lupus. |
NMDA, SLE, TRPC6 |
| 98 |
2015 |
[Systemic lupus erythematosus of the nervous system--selected aspects]. |
CNS |
| 99 |
2014 |
Association between anti-U1 ribonucleoprotein antibodies and inflammatory mediators in cerebrospinal fluid of patients with neuropsychiatric systemic lupus erythematosus. |
Abs, CSF, IMs |
| 100 |
2014 |
Association of cerebrospinal fluid anti-Sm antibodies with acute confusional state in systemic lupus erythematosus. |
ACS, BBB, CSF, ELISA |
|
A Search Service for Abbreviation / Long Form
